A new analysis released on Thursday, 12 June by the National Security Commission on Emerging Biotechnology (NSCEB) warns that China is advancing faster than the United States across every key dimension of biotechnology — national strategy, regulation, infrastructure, investment, and data — raising alarm that Washington could cede its long-held leadership in a sector now seen as central to both economic and military power.

Beijing's Five-Year Plan and Biotech Ambitions

According to the commission, the Chinese Communist Party (CCP) has treated biotechnology as a national priority for two decades and has doubled down on that commitment in its 2026 Five-Year Plan. The plan designates biomedicine, biomanufacturing, brain-computer interface technologies, and pharmaceuticals as strategic sectors — placing them alongside artificial intelligence and quantum computing. The report argues that Beijing is not merely setting targets but actively translating them into government policy and industrial capacity at a pace Washington has yet to match.

By contrast, the United States still lacks a unified national biotechnology strategy. Bipartisan lawmakers introduced coordinating legislation in 2025, but it has not yet been enacted into law.

Regulatory Speed and Clinical Trial Leadership

The NSCEB report highlights China's regulatory overhaul as a significant competitive edge. Reforms implemented over the past decade have created a two-track approval system for drugs and medical products, allowing researchers to obtain preliminary human data more quickly. By 2024, China led the world in the number of clinical trials launched annually, according to the report. Notably, several US-based pharmaceutical companies now conduct first-in-human trials in China — a striking reversal that underscores the depth of the regulatory gap.

Manufacturing Gap Widens

The report points to a widening divergence in biomanufacturing capacity. While the US Congress has appropriated funding for bioindustrial facilities under the BioMADE programme, the commission noted that none of the three announced facilities are yet operational. China, meanwhile, announced public-private partnerships with 43 companies in 2025 to build biomanufacturing pilot plants across the country — a concrete, large-scale deployment that contrasts sharply with Washington's still-pending infrastructure.

Data, Investment, and National Security Implications

The commission also flagged Beijing's use of government-backed investment vehicles to support strategic biotech industries and its treatment of biological data as a national resource — feeding artificial intelligence systems and accelerating biotechnology development in ways that have direct national security implications. The report warns that China is actively seeking to integrate biotechnology into its warfighting capabilities, and that advances in the field could directly strengthen Chinese military power.

What the Commission Is Calling For

NSCEB Chair Senator Todd Young acknowledged partial progress but struck an urgent tone. 'China's biotech strategy is clear, and it's a playbook we have seen before — corner the market, scale the technology, and then strangle supply chains to gain strategic advantages,' he said. He added: 'The Chinese government is leveraging biotechnology policy more effectively than the United States, and we are starting to fall behind on innovation and scale-up.' Senator Young noted that US policymakers have moved forward on more than half of the NSCEB's recommendations over the past year but called for swift action on the remaining priorities — particularly regulatory streamlining and manufacturing infrastructure. The NSCEB was established by Congress to assess the national security implications of emerging biotechnology and to recommend policies that strengthen US competitiveness. Its April 2025 action plan laid out a roadmap covering national strategy, faster regulation, expanded manufacturing, greater investment, and stronger biological data infrastructure. With biotechnology now sitting alongside semiconductors, AI, and quantum computing as a defining front in the US-China technology rivalry, the commission's latest report is an escalating warning that the window for Washington to act may be narrowing.